4G Typhoid vaccine from Bharat Biotech - The New Indian Express

4G Typhoid vaccine from Bharat Biotech

Published: 27th August 2013 08:36 AM

Last Updated: 27th August 2013 08:37 AM

Bharat Biotech International Ltd on Monday launched a new typhoid vaccine, claimed to be the world’s first clinically proven typhoid conjugate vaccine.

The privately-held company, which spent Rs 65 crore to develop the vaccine over a period of eight years of internal R&D, is now targeting a business of Rs 100 crore from this segment.

Currently, Bharat Biotech produces and markets a third-generation typhoid vaccine, which contributes about Rs 50 crore in revenue.

“This is the first typhoid conjugate vaccine to get a licence after going through the full scale clinical trial process,” said Krishna Ella, CMD, Bharat Biotech.

Typhoid vaccines currently available fall short of two major factors — long-term protection and protection for children below 2 years, an age group that’s mostly affected.

Titled TYPBAR-TCV, Bharat Bio’s fourth generation typhoid vaccine, is expected to address the shortcomings including low immunogenecity and being effective for a shorter duration. “We hope this vaccine will reach millions of people and help reduce the burden of this devastating disease in infants and children,” Ella added.

Bharat Biotech, which exports a substantial volume of typhoid vaccines to Pakistan and Bangladesh for both civilian and army requirements, will follow a dual pricing model for public and the private market.

Disclaimer: We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the NIE editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.


Recent Activity

Pinterest Google Plus Twitter Facebook tumblr RSS Mobile Site apple Newshunt